Onpattro, INN - patisiran
Recent advances in siRNA delivery mediated by lipid-based nanoparticles - ScienceDirect
ONPATTRO (patisiran) small interfering RNA for Treatment of Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs | Nature Nanotechnology
Reimbursement Guide for ONPATTRO® (patisiran)
Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran | SpringerLink
Onpattro, INN - patisiran
Prediction of the complex structure of patisiran (Onpattro). The input... | Download Scientific Diagram
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation - American Journal of Transplantation
Structure of patisiran. | Download Scientific Diagram
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis | SpringerLink
FULL PRESCRIBING INFORMATION: CONTENTS*
ONPATTRO® (patisiran) Treatment Journal
ONPATTRO® (patisiran) Dosing and Preparation Guide
Biomedicines | Free Full-Text | Patisiran Enhances Muscle Mass after Nine Months of Treatment in ATTRv Amyloidosis: A Study with Bioelectrical Impedance Analysis and Handgrip Strength
Patisiran - an overview | ScienceDirect Topics
Pharmaceuticals | Free Full-Text | 2018 FDA Tides Harvest
Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis | Neurodegenerative Disease Management
Medicines Management Programme Managed Access Protocol – Patisiran (Onpattro®) for the treatment of hereditary transthyretin-
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
FULL PRESCRIBING INFORMATION: CONTENTS*
Patisiran - wikidoc
Advances in oligonucleotide drug delivery | Nature Reviews Drug Discovery
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
